Women And Lung Cancer Researchers Look For Gender Connection Female
Cancer Patients Sought For Large Scale Clinical Trial

Women And Lung Cancer Researchers Look For Gender Connection Female Cancer Patients Sought For Large Scale Clinical Trial

Women and​ ​ Lung Cancer Researchers Look for​ Gender Connection

Female Cancer Patients Sought for​ LargeScale Clinical Trial
According to a​ recent survey on health concerns, women fear breast cancer most. ​
Despite the​ fears expressed in the​ survey, conducted by the​ International Communications Research of​ Media for​ the​ Society of​ Womens Health Research in 2018, lung cancer is​ actually the​ leading cancer killer of​ women. ​
Lung cancer takes the​ lives of​ approximately 68,000 women each year.
While smoking is​ the​ biggest risk factor for​ lung cancer, there is​ growing evidence that points to gender differences in the​ risk of​ developing lung cancer and​ ​ the​ implications for​ treating the​ disease in men and​ ​ women. ​

For example, while the​ number of​ men diagnosed with lung cancer has been going down, the​ number of​ women has risen 60 percent since 1990. ​
In addition, women who are nonsmokers are 2.5 times more likely to develop lung cancer than men who are nonsmokers. ​

Scientific evidence points to estrogen as​ a​ factor in the​ difference between how lung cancer acts in men versus women. ​
That biological difference promises to have important implications for​ lung cancer treatments. ​

It is​ believed that the​ estrogen in women may influence lung tumor growth by causing the​ synthesis of​ tumorpromoting proteins. ​
Since women have higher levels of​ estrogen than men, and​ ​ younger women have higher levels of​ estrogen than older women, this may in part be responsible for​ their higher risk for​ nonsmall cell lung cancer NSCLC. ​

Developing therapies that are favorably influenced by estrogen may provide a​ gendertargeted therapeutic approach to the​ treatment of​ the​ disease. ​

Researchers are currently studying a​ novel approach to targeting lung cancer in women that relies on a​ chemotherapy agent that exploits the​ presence of​ estrogen in women and​ ​ its effect on the​ metabolism of​ proteins in the​ cancer cell. ​
Cell Therapeutics, Inc. ​
CTI developed XYOTAX paclitaxel poliglumex initially as​ a​ lung cancer ​Drug​ for​ all patientsregardless of​ gender. ​
Retrospective analysis of​ two Phase III clinical trials found the​ ​Drug​, as​ compared to standard chemotherapy treatments, had a​ significant survival advantage in women while having equivalent survival in men. ​

New clinical trial
Now, Cell Therapeutics is​ embarking on another clinical study exclusively in women to see if​ ​ the​ theory proves true in a​ larger population of​ women. ​
The trial, known as​ PIONEER, is​ the​ first approval trial for​ lung cancer exclusively targeting women and​ ​ is​ expected to enroll 600 patients with advanced lung cancer.

You Might Also Like:

No comments:

Powered by Blogger.